Viking Therapeutics, Inc. (VKTX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Viking Therapeutics, Inc. (VKTX) is down 16.6% since the beginning of the year. At $29 per share, VKTX is trading 32.0% below its 52-week high of $43. Investors who bought $1,000 worth of VKTX shares 5 years ago would now be looking at an investment worth $5,575.

Viking Therapeutics, Inc. (VKTX) has returned -16.63% so far this year and 10.22% over the past 12 months. Looking at the last ten years, VKTX has achieved an annualized return of 35.08%, outperforming the S&P 500 Index benchmark, which averaged 13.66% per year.

Based on dividend-adjusted daily data since Apr 29, 2015, VKTX's average daily return is +0.21%, while the average monthly return is +4.10%. At this rate, an investment would double in approximately 1.4 years.

Historically, 41% of months were positive and 59% were negative. The best month was Feb 2024 with a return of +219.2%, while the worst month was Nov 2015 at -43.3%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 9 months.

On a daily basis, VKTX closed higher 46% of trading days. The best single day was Feb 27, 2024 with a return of +121.0%, while the worst single day was Aug 19, 2025 at -42.1%.

Viking Therapeutics, Inc. has an annualized alpha of 47.77%, beta of 1.10, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since April 30, 2015.

• This stock participated in 139.50% of S&P 500 Index downside but only 137.58% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

VKTX ranks 47 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Viking Therapeutics, Inc. (VKTX) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Viking Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Viking Therapeutics, Inc. was 90.41%, occurring on Aug 2, 2017. Recovery took 208 trading sessions.

The current Viking Therapeutics, Inc. drawdown is 68.96%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Viking Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Viking Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.